Phaseline

Targets › BCL2L2-PABPN1

BCL2L2-PABPN1: drug programs, companies and trials

1 program from 1 company in 9 trials: 7 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on BCL2L2-PABPN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbVieNavitoclax
Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor
BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1Phase 3Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma …Dec 2026

Conditions

Myelofibrosis (MF) (1) Myeloproliferative Neoplasm (1) Mantle Cell Lymphoma Refractory (1) High Grade Serous Carcinoma (1) Myeloid Malignancy (1) Refractory Acute Lymphoblastic Leukemia (1) Recurrent Acute Myeloid Leukemia (1) Metastatic Malignant Solid Neoplasm (1) Clinical Stage III Cutaneous Melanoma AJCC v8 (1)

Modalities

small molecule (1)

Companies

AbbVie (1)

Related targets

BCL2 (1) BCL2L1 (1) BCL2L2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.